<DOC>
	<DOCNO>NCT01524679</DOCNO>
	<brief_summary>A prospective , randomised , open-label phase IIb clinical trial assess effect pegylated interferon alfa-2a ( Pegasys® ) 180 μg weekly 48 week add ongoing nucleos ( ) ide base treatment patient chronic HBeAg-negative hepatitis B The primary objective trial investigate whether add-on pegylated interferon alfa-2a continued treatment nucleos ( ) ide analogues increase percentage patient significant decrease ( ≥ 1log10 ) HBs antigen 48 week . 170 Patients chronic hepatitis B , HBe antigen negative , already treat oral antiviral regimen nondetectable viral load least 12 month include .</brief_summary>
	<brief_title>Peg-interferon ADDed Ongoing Nucleos ( ) Ide Based Treatment Patients With Chronic Hepatitis B Induce Decrease HBs-Antigen</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Chronic hepatitis B , HBe antigen negative treatment stable oral antiviral treatment ( contain telbivudine ) fully suppress viral load least 12 month ( limit detection conventional HBVPCR assay , i.e . &lt; 116 IU / ml ) . 1870 y willingness ability give inform consent follow study procedure willingness use adequate contraception contraindication treatment pegylated interferon , e.g . depression , uncontrolled epilepsy , autoimmune disease , pregnancy , leukocytopenia thrombocytopenia screening , etc . active alcohol drug abuse preexist polyneuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic hepatitis B</keyword>
</DOC>